Common questions about Aerospan (FAQ)
Q: How long does it usually take to notice Aerospan working?
Aerospan is intended for long-term maintenance treatment, not for immediate relief of sudden breathing problems. According to official product information, for the maximum therapeutic effect to be achieved, continuous use for two to four weeks may be required.
Q: Does Aerospan start working right away?
Official regulatory documents confirm that Aerospan is explicitly not indicated for the relief of an acute bronchospasm. This means it is not intended for use when quick relief is needed for sudden or severe breathing difficulties.
Q: How does Aerospan compare to other common inhalers?
Aerospan is classified as an Inhaled Glucocorticoid, which is a type of controller medicine used daily to manage chronic inflammation. This descriptive classification separates it from other inhalers, such as those that provide immediate, short-acting relief (rescue inhalers).
Q: What is the difference between Aerospan and a rescue inhaler?
A rescue inhaler is a separate medication whose function is limited to the immediate relief of acute asthma attacks or bronchospasm, which Aerospan is not indicated to treat. Aerospan is used as a controller medication for daily maintenance to prevent symptoms from occurring.
Q: What is the age limit for using Aerospan?
Official regulatory documents state that the medicine is formally authorized for use in adults and pediatric patients 6 years of age and older. Use is not established for children younger than six years of age.
Q: Can Aerospan be used by pregnant or breastfeeding individuals?
Regarding pregnancy, official information advises that the medication should be used only when the potential benefit is determined to outweigh the potential risk to the fetus. For breastfeeding individuals, caution is recommended, as it is unknown if the drug is excreted into human milk.
Q: Does Aerospan affect blood pressure?
While the drug's label does not list blood pressure changes as a common side effect, symptoms of adrenal insufficiency—a potential risk associated with long-term systemic corticosteroid effects—can include low blood pressure (hypotension).
Q: What is the typical timeframe for seeing the maximum benefit from Aerospan?
The timeframe for achieving the maximum therapeutic effect is often noted in official documents. Continuous daily therapy for generally two to four weeks may be required for the maximum effect to be achieved.
Q: Are headaches a common side effect of Aerospan?
Yes, headache is listed in regulatory documents as a common adverse reaction reported during clinical studies. In these studies, common reactions typically occurred in approximately 1% to 10% of individuals.
Q: What happens if I stop using Aerospan suddenly?
Official regulatory warnings exist against the abrupt discontinuation of the medication. This caution is due to the potential risk of adrenal insufficiency and possible withdrawal symptoms for individuals, particularly those who have been transferred from long-term systemic (oral) corticosteroid therapy.
Q: Can Aerospan cause anxiety or mood changes?
Official information indicates that depression and irritability are noted as potential symptoms of withdrawal. These symptoms may be experienced by patients who are transferred from long-term oral corticosteroid therapy.
Q: Does using Aerospan affect your bones or increase osteoporosis risk?
Regulatory documents indicate that long-term use of inhaled corticosteroids, like Aerospan, is associated with a potential reduction in bone mineral density. Because of this association, the monitoring of bone mineral density may be warranted during long-term use.
Q: Is it normal to feel a different taste in my mouth after using Aerospan?
Yes, a different taste in the mouth is listed as a documented adverse reaction known as taste perversion. This information is included in the safety and side effect sections of regulatory documents.
Q: What evidence supports the use of Aerospan for its approved conditions?
The medicine's use for maintenance asthma treatment is supported by clinical trials which have shown that treatment is associated with improvements in key lung function metrics, such as forced expiratory volume in one second (FEV1), in patients with persistent asthma.
Q: Are there specific criteria for who should not use Aerospan?
Official product information lists absolute prohibitions, known as contraindications. These include not using the drug if a patient has acute episodes of asthma, status asthmaticus, or known hypersensitivity to any component. Conditional use requires caution for individuals with certain comorbidities.
Q: Why do official documents caution against stopping Aerospan abruptly?
The caution against abrupt discontinuation is due to the potential risk of adrenal insufficiency in some individuals. This is particularly relevant for patients who have been switched from systemic (oral) corticosteroids, as stopping suddenly could lead to withdrawal symptoms.
Q: Does Aerospan interact with other common asthma or COPD medications?
Regulatory documents warn against combining Aerospan with other systemic or inhaled corticosteroid products due to the risk of systemic effects. A warning also exists regarding combination with an additional medicine containing a LABA (Long-Acting Beta Agonist) due to potential overdose risks.
Q: What does Aerospan do to the airways?
Aerospan contains an inhaled corticosteroid that works directly in the airways to reduce inflammation. This potent anti-inflammatory action helps to suppress the underlying swelling and irritation associated with chronic respiratory conditions.
Q: Is Aerospan considered a maintenance drug?
Yes, the official general purpose of the drug is to provide maintenance treatment and prophylactic therapy by directly managing chronic airway inflammation. It is officially designated as a controller medication.
Q: Why is proper inhalation technique important for Aerospan?
Proper technique ensures that the medication is delivered locally to the lungs for the maximum effect. It is also linked to reducing local adverse effects, such as oral fungal infections, which may be mitigated by following post-use instructions like rinsing the mouth.
